PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Polaryx Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.92+0.04 (+2.13%)

Close on Oct 19, 2026

Market cap: $92.69M
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Polaryx Therapeutics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Polaryx Therapeutics filed with the SEC

Sep 1, 2026, 4:30 PM ET
PRESS RELEASE, DATED SEPTEMBER 1, 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
May 28, 2026, 4:31 PM ET
PRESS RELEASE DATED MAY 28, 2026
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K